| Category | Product Name | CAS Number | Formula | Assay | Specifications |
| Ibrutinib | (R)-tert-Butyl 3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate | CAS No.1022150-11-3 | C27H30N6O3 | 98% | / |
| 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile | CAS No.330792-70-6 | C16H12N4O | 98% | CP, EP, As Required | |
| Ibrutinib | CAS No.936563-96-1 | C25H24N6O2 | 98% | / | |
| 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine | CAS No.330786-24-8 | C17H13N5O | 98% | / | |
| (S)-1-Boc-3-hydroxypiperidine | CAS No.143900-44-1 | C10H19NO3 | 98% | / | |
| 3-(4-Phenoxy-phenyl)-1-piperidin-3-yl-1H-pyrazolo[3,4-d]pyriMidin-4-ylaMine | CAS No.1022150-12-4 | C22H2N6O | 98% | / | |
| Ruxolitinib | Ruxolitinib Phosphate | CAS No.1092939-17-7 | C17H21N6O4P | 98% | CP, EP, In-house, As Required |
| 4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine | CAS No.941685-26-3 | C12H18ClN3OSi | 98% | / | |
| 3-cyclopentylacrylonitrile | CAS No.591769-05-0 | C9H12 | 98% | ||
| Baricitinib | 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | CAS No.1029716-44-6 | C13H23BN2O3 | 98% | / |
| 2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile | CAS No.1187595-85-2 | C7H10N2O2S | 98% | / | |
| 4-(1h-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7h-pyrrolo[2,3-d]pyrimidine | CAS No.941685-27-4 | C15H21N5O | 98% | / | |
| Baricitinib Phosphate | CAS No.1187595-84-1 | C16H20N7O6PS | 98% | / | |
| Tofacitinib | N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | CAS No.477600-74-1 | C13H19N5 | 98% | / |
| Tofacitinib Citrate | CAS No.540737-29-9 | C22H28N6O8 | 98% | / | |
| 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine | CAS No.3680-69-1 | C6H4ClN3 | 98% | / | |
| (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride | CAS No.1062580-52-2 | C14H23ClN2 | 98% | / | |
| N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine | CAS No.923036-30-0 | C27H31N5O2S | 98% | CP, EP, As Required | |
| Lenalidomide | Lenalidomide | CAS No.191732-72-6 | C13H13N3O3 | 98% | / |
| Methyl 2-bromomethyl-3-nitrobenzoate | CAS No.98475-07-1 | C9H8BrNO4 | 98% | / | |
| Pomalidomide | Pomalidomide | CAS No.19171-19-8 | C13H11N3O4 | 98% | CP, EP, As Required |
| 2,6-Dioxopiperidine-3-ammonium chloride | CAS No.24666-56-6 | C5H9ClN2O2 | 98% | / | |
| Niraparib | (S)-tert-butyl 3-(4-aMinophenyl)piperidine-1-carboxylate | CAS No.1171197-20-8 | C16H24N2O2 | 98% | / |
| Methyl 3-formyl-2-nitrobenzoate | CAS No.138229-59-1 | C9H7NO5 | 98% | / | |
| Niraparib tosylate monohydrate | CAS No.1613220-15-7 | C26H28N4O4S | 98% | CP, EP, As Required | |
| Niraparib (free free alkali form) | CAS No.1038915-60-4 | C19H20N4O | 98% | / | |
| Carfilzomib | Carfilzomib | CAS No.868540-17-4 | C40H57N5O7 | 98% | CP, EP, In-house, As Required |
| Ixazomib | Ixazomib Citrate | CAS No.1201902-80-8 | C20H23BCl2N2O9 | 98% | CP, EP, In-house, As Required |
| 2-(2,5-dichlorobenzamido)acetic acid | CAS No.667403-46-5 | C9H7Cl2NO3 | 98% | / | |
| (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate | CAS No.179324-87-9 | C17H29BF3NO4 | 98% | / | |
| Enasidenib Mesylate | 6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4(1H,3H)-dione | CAS No.1446507-38-5 | C9H5F3N4O2 | 98% | / |
| 4-Amino-2-trifluoromethylpyridine | CAS No.147149-98-2 | C6H5F3N2 | 98% | / | |
| Enasidenib mesylate | CAS No.1650550-25-6 | C20H21F6N7O4S | 98% | CP, EP, As Required | |
| 4-chloro-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine | CAS No.1446507-68-1 | C15H7ClF6N6 | 98% | / | |
| 1-Amino-2-methylpropan-2-ol | CAS No.2854-16-2 | C4H11NO | 98% | / | |
| Pralatrexate | 6-(Bromomethyl)-2,4-pteridinediamine hydrobromide | CAS No.52853-40-4 | C7H8Br2N6 | 98% | / |
| Raltitrexed | Raltitrexed | CAS No.112887-68-0 | C21H22N4O6S | 98% | CP, EP, As Required |
| 5-[N-(tert-butoxycarbonyl)-N-methylamino]-2-thiophenecarboxylic acid | CAS No.131052-68-1 | C11H15NO4S | 98% | / | |
| 5-Nitrothiophene-2-carboxylicacid | CAS No.6317-37-9 | C5H3NO4S | 98% | / | |
| 6-Bromomethyl-3,4-dihydro-2-methyl-quinazolin-4-one | CAS No.112888-43-4 | C10H9BrN2O | 98% | CP, EP, As Required | |
| Belumosudil Mesylate | Belumosudil mesylate | CAS No.2109704-99-4 | C27H28N6O5S | 98% | CP, EP, In-house, As Required |
| N-isopropyl-2-(3-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide | CAS No.2121561-39-3 | C19H19N3O3 | 98% | / | |
| Eltrombopag Olamine | Eltrombopag Olamine | CAS No.496775-62-3 | C27H29N5O5 | 98% | CP, EP, In-house, As Required |
| 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid | CAS No.376608-65-0 | C14H25NO10 | 98% | / | |
| 3-bromo-2-methoxyaniline | CAS No.116557-46-1 | C7H8BrNO | 98% | / | |
| 1-(3,4-dimethylphenyl)-3-methyl-3-pyrazolin-5-one | CAS No.18048-64-1 | C12H14N2O | 98% | / | |
| Calcium Levofolinate | L-Calcium Levofolinate | CAS No.80433-71-2 | C20H25CaN7O7 | 99% | CP, EP, In-house, As Required |
| Leucovorin calcium | CAS No.1492-18-8 | C20H25CaN7O7 | 99% | CP, EP, In-house, As Required | |
| Methotrexate | Methotrexate | CAS No.59-05-2 | C20H22N8O5 | 98% | CP, EP, In-house, As Required |
| Pyrimidinetetramine sulfate | CAS No.5392-28-9 | C4H10N6O4S | 98% | / | |
| 1,1,3-Tribromoacetone | CAS No.3475-39-6 | C3H3Br3O | 98% | / | |
| 2,4-diamino-6-(hydroxymethyl)-pteridine hydrochloride | CAS No.73978-41-3 | C7H8N6O·HCl | 98% | / | |
| 2,4-diamino-6-(hydroxymethyl)-pteridine | CAS No.945-24-4 | C7H8N6O | 98% | / | |
| 6-(chloromethyl)pteridine-2,4-diamine monohydrochloride | CAS No.82778-08-3 | C7H8Cl2N6 | 98% | / | |
| 4-(Methylamino)benzoic acid | CAS No.10541-83-0 | C8H9NO2 | 98% | / | |
| Methotrexate Disodium Salt | CAS No.7413-34-5 | C20H20N8O5Na2 | 98% | / |
Be the first to get our latest styles and offers.
Building B,No.6 Xingzhi Road,Nanjing Economic and Technological Development Zone
Copyright © 2026 Farmasino Medical Co.,Ltd. All rights reserved. - Privacy Policy
EN
